Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy

Summary

To develop an educational patient decision aid for advanced cancer patients to prepare them to have conversations with their clinicians about treatment options (Treatments in Advanced cancer - Decision Aid, TA-DA).

Eligibility

Inclusion Criteria:

1. Clinicians (Part I/II/III):

   MD Anderson medical oncologists and APPs who provide care to patients with advanced cancer
2. Patients (Part I/II/III):

   Age 18 or over
   * Diagnosis of advanced cancer (i.e., metastatic, relapsed, and/or incurable disease as defined by the treating oncologist) who has received at least 2 lines of palliative systemic therapy\*
   * Patient-rated ECOG performance status of 1-3 for Part I/II and 2-3 for Part III
   * Able to make treatment decisions based on the clinical judgement of the oncology team
   * English speaking

     * patient has started, is receiving, and/or has completed second-line palliative systemic therapy or beyond
3. Caregivers (Part I/II/III):

   * Age 18 or older
   * Currently a primary caregiver to a patient who satisfies the patient eligibility criteria listed above
   * For the study purposes, a primary caregiver is defined as:

     * someone who provides physical, emotional, decisional and/or logistical assistance to the patient regularly (e.g. daily, weekly);
     * can be a family member, friend, or other individual in a close relationship with the patient;
     * must be identified by the patient and self-identify as the primary person providing caregiving support to the patient
   * Able to provide informed consent and participate in the study
   * English speaking

Exclusion Criteria:

Any patient who meets any of the following criteria will be excluded from participation in this study:

* (Part I/II/III): Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker as determined by the clinical team
* (Part III only): Participants in Part I and II

Conditions2

Locations1 site

Browse More Trials